Opioid-induced hyperalgesia: Cellular and molecular mechanisms

Neuroscience

Volumn 338, Issue , 2016, Pages 160-182

  Roeckel, Laurie Anne ^a,b,c,d   Le Coz, Glenn Marie ^b   Gavériaux Ruff, Claire ^a,b,c,d   Simonin, Frédéric ^b  

^a INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c CNRS   (France)

^d INSERM   (France)

Author keywords

morphine; mu opioid receptor; neuroinflammation; opiates; opioid induced hyperalgesia; pain

Indexed keywords

ADENOSINE TRIPHOSPHATE; BETA ARRESTIN 2; BRAIN DERIVED NEUROTROPHIC FACTOR; CHEMOKINE RECEPTOR CX3CR1; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR4; CXCL1 CHEMOKINE; EPHRIN B RECEPTOR; EPHRIN RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCYTE CHEMOTACTIC PROTEIN 1; MU OPIATE RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; POTASSIUM CHLORIDE COTRANSPORTER 2; PURINERGIC P2X4 RECEPTOR; RANTES; SEROTONIN 3 RECEPTOR; STROMAL CELL DERIVED FACTOR 1; TACHYKININ NK1 RECEPTOR; TACHYKININ RECEPTOR; TOLL LIKE RECEPTOR 4; TRANSIENT RECEPTOR POTENTIAL CHANNEL M8; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANILLOID RECEPTOR 1; NARCOTIC ANALGESIC AGENT;

ASTROCYTE; ENZYME ACTIVATION; ENZYME INHIBITION; EPIGENETICS; FACILITATION; HUMAN; HYPERALGESIA; IN VITRO STUDY; IN VIVO STUDY; LONG TERM POTENTIATION; MICROGLIA; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OPIOID INDUCED HYPERALGESIA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; ROSTRAL VENTROMEDIAL MEDULLA; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; CHEMICALLY INDUCED; GENETICS; METABOLISM;

ANALGESICS, OPIOID; ANIMALS; HUMANS; HYPERALGESIA;

EID: 84994000020     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2016.06.029     Document Type: Review

References (264)

1. Aguado, D., Abreu, M., Benito, J., Garcia-Fernandez, J., Gomez de Segura, I.A., Amitriptyline, minocycline and maropitant reduce the sevoflurane minimum alveolar concentration and potentiate remifentanil but do not prevent acute opioid tolerance and hyperalgesia in the rat: a randomised laboratory study. Eur J Anaesthesiol 32 (2015), 248–254.
2. Aley, K.O., Messing, R.O., Mochly-Rosen, D., Levine, J.D., Chronic hypersensitivity for inflammatory nociceptor sensitization mediated by the epsilon isozyme of protein kinase C. J Neurosci 20 (2000), 4680–4685.
3. Alizadeh, Z., Fereidoni, M., Behnam-Rassouli, M., Hosseini, S., Role of C-fibers in pain and morphine induced analgesia/hyperalgesia in rats. Iran J Neurol 13 (2014), 19–27.
4. Andersen, G., Christrup, L., Sjogren, P., Relationships among morphine metabolism, pain and side effects during long-term treatment: an update. J Pain Symptom Manage 25 (2003), 74–91.
5. Angst, M.S., Clark, J.D., Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology 104 (2006), 570–587.
6. Antal, M., Fukazawa, Y., Eordogh, M., Muszil, D., Molnar, E., Itakura, M., Takahashi, M., Shigemoto, R., Numbers, densities, and colocalization of AMPA- and NMDA-type glutamate receptors at individual synapses in the superficial spinal dorsal horn of rats. J Neurosci 28 (2008), 9692–9701.
7. Araldi, D., Ferrari, L.F., Levine, J.D., Repeated mu-opioid exposure induces a novel form of the hyperalgesic priming model for transition to chronic pain. J Neurosci 35 (2015), 12502–12517.
8. Arout, C.A., Caldwell, M., McCloskey, D.P., Kest, B., C-Fos activation in the periaqueductal gray following acute morphine-3beta-D-glucuronide or morphine administration. Physiol Behav 130 (2014), 28–33.
9. Arout, C.A., Caldwell, M., Rossi, G., Kest, B., Spinal and supraspinal N-methyl-D-aspartate and melanocortin-1 receptors contribute to a qualitative sex difference in morphine-induced hyperalgesia. Physiol Behav 147 (2015), 364–372.
10. Arout, C.A., Edens, E., Petrakis, I.L., Sofuoglu, M., Targeting opioid-induced hyperalgesia in clinical treatment: neurobiological considerations. CNS Drugs 29 (2015), 465–486.
11. Austin, P.J., Berglund, A.M., Siu, S., Fiore, N.T., Gerke-Duncan, M.B., Ollerenshaw, S.L., Leigh, S.J., Kunjan, P.A., Kang, J.W., Keay, K.A., Evidence for a distinct neuro-immune signature in rats that develop behavioural disability after nerve injury. J Neuroinflammation, 12, 2015, 96.
12. Bai, L., Zhai, C., Han, K., Li, Z., Qian, J., Jing, Y., Zhang, W., Xu, J.T., Toll-like receptor 4-mediated nuclear factor-kappaB activation in spinal cord contributes to chronic morphine-induced analgesic tolerance and hyperalgesia in rats. Neurosci Bull 30 (2014), 936–948.
13. Bannister, K., Sikandar, S., Bauer, C.S., Dolphin, A.C., Porreca, F., Dickenson, A.H., Pregabalin suppresses spinal neuronal hyperexcitability and visceral hypersensitivity in the absence of peripheral pathophysiology. Anesthesiology 115 (2011), 144–152.
14. Basbaum, A.I., Bautista, D.M., Scherrer, G., Julius, D., Cellular and molecular mechanisms of pain. Cell 139 (2009), 267–284.
15. Basso, L., Boue, J., Bourreille, A., Dietrich, G., Endogenous regulation of inflammatory pain by T-cell-derived opioids: when friend turns to foe. Inflamm Bowel Dis 20 (2014), 1870–1877.
16. Bautista, D.M., Siemens, J., Glazer, J.M., Tsuruda, P.R., Basbaum, A.I., Stucky, C.L., Jordt, S.E., Julius, D., The menthol receptor TRPM8 is the principal detector of environmental cold. Nature 448 (2007), 204–208.
17. Beaudry, H., Gendron, L., Moron, J.A., Implication of delta opioid receptor subtype 2 but not delta opioid receptor subtype 1 in the development of morphine analgesic tolerance in a rat model of chronic inflammatory pain. Eur J Neurosci 41 (2015), 901–907.
18. Benrath, J., Brechtel, C., Stark, J., Sandkuhler, J., Low dose of S+-ketamine prevents long-term potentiation in pain pathways under strong opioid analgesia in the rat spinal cord in vivo. Br J Anaesth 95 (2005), 518–523.
19. Berta, T., Liu, T., Liu, Y.C., Xu, Z.Z., Ji, R.R., Acute morphine activates satellite glial cells and up-regulates IL-1beta in dorsal root ganglia in mice via matrix metalloprotease-9. Mol Pain, 8, 2012, 18.
20. Berta, T., Liu, Y.C., Xu, Z.Z., Ji, R.R., Tissue plasminogen activator contributes to morphine tolerance and induces mechanical allodynia via astrocytic IL-1beta and ERK signaling in the spinal cord of mice. Neuroscience 247 (2013), 376–385.
21. Besse, D., Lombard, M.C., Zajac, J.M., Roques, B.P., Besson, J.M., Pre- and postsynaptic distribution of mu, delta and kappa opioid receptors in the superficial layers of the cervical dorsal horn of the rat spinal cord. Brain Res 521 (1990), 15–22.
22. Bianchi, E., Galeotti, N., Menicacci, C., Ghelardini, C., Contribution of G inhibitory protein alpha subunits in paradoxical hyperalgesia elicited by exceedingly low doses of morphine in mice. Life Sci 89 (2011), 918–925.
23. Bianchi, E., Norcini, M., Smrcka, A., Ghelardini, C., Supraspinal Gbetagamma-dependent stimulation of PLCbeta originating from G inhibitory protein-mu opioid receptor-coupling is necessary for morphine induced acute hyperalgesia. J Neurochem 111 (2009), 171–180.
24. Block, L., Bjorklund, U., Westerlund, A., Jorneberg, P., Biber, B., Hansson, E., A new concept affecting restoration of inflammation-reactive astrocytes. Neuroscience 250 (2013), 536–545.
25. Bodnar, R.J., Kest, B., Sex differences in opioid analgesia, hyperalgesia, tolerance and withdrawal: central mechanisms of action and roles of gonadal hormones. Horm Behav 58 (2010), 72–81.
26. Bohn, L.M., Gainetdinov, R.R., Lin, F.T., Lefkowitz, R.J., Caron, M.G., Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. Nature 408 (2000), 720–723.
27. Breivik, H., Collett, B., Ventafridda, V., Cohen, R., Gallacher, D., Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 10 (2006), 287–333.
28. Breivik, H., Eisenberg, E., O'Brien, T., The individual and societal burden of chronic pain in Europe: the case for strategic prioritisation and action to improve knowledge and availability of appropriate care. BMC Public Health, 13, 2013, 1229.
29. Cahill, C.M., Taylor, A.M., Cook, C., Ong, E., Moron, J.A., Evans, C.J., Does the kappa opioid receptor system contribute to pain aversion?. Front Pharmacol, 5, 2014, 253.
30. Calvo, M., Dawes, J.M., Bennett, D.L., The role of the immune system in the generation of neuropathic pain. Lancet Neurol 11 (2012), 629–642.
31. Carullo, V., Fitz-James, I., Delphin, E., Opioid-induced hyperalgesia: a diagnostic dilemma. J Pain Palliat Care Pharmacother 29 (2015), 378–384.
32. Caterina, M.J., Leffler, A., Malmberg, A.B., Martin, W.J., Trafton, J., Petersen-Zeitz, K.R., Koltzenburg, M., Basbaum, A.I., Julius, D., Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science (New York, NY) 288 (2000), 306–313.
33. Celerier, E., Laulin, J., Larcher, A., Le Moal, M., Simonnet, G., Evidence for opiate-activated NMDA processes masking opiate analgesia in rats. Brain Res 847 (1999), 18–25.
34. Celerier, E., Laulin, J.P., Corcuff, J.B., Le Moal, M., Simonnet, G., Progressive enhancement of delayed hyperalgesia induced by repeated heroin administration: a sensitization process. J Neurosci 21 (2001), 4074–4080.
35. Celerier, E., Rivat, C., Jun, Y., Laulin, J.P., Larcher, A., Reynier, P., Simonnet, G., Long-lasting hyperalgesia induced by fentanyl in rats: preventive effect of ketamine. Anesthesiology 92 (2000), 465–472.
36. Celerier, E., Simonnet, G., Maldonado, R., Prevention of fentanyl-induced delayed pronociceptive effects in mice lacking the protein kinase Cgamma gene. Neuropharmacology 46 (2004), 264–272.
37. Chabot-Dore, A.J., Schuster, D.J., Stone, L.S., Wilcox, G.L., Analgesic synergy between opioid and alpha2 -adrenoceptors. Br J Pharmacol 172 (2015), 388–402.
38. Chao, Y.C., Xie, F., Li, X., Guo, R., Yang, N., Zhang, C., Shi, R., Guan, Y., Yue, Y., Wang, Y., Demethylation regulation of BDNF gene expression in dorsal root ganglion neurons is implicated in opioid-induced pain hypersensitivity in rats. Neurochem Int, 2016.
39. Chen, L., Huang, L.Y., Sustained potentiation of NMDA receptor-mediated glutamate responses through activation of protein kinase C by a mu opioid. Neuron 7 (1991), 319–326.
40. Chen, L., Sein, M., Vo, T., Amhmed, S., Zhang, Y., Hilaire, K.S., Houghton, M., Mao, J., Clinical interpretation of opioid tolerance versus opioid-induced hyperalgesia. J Opioid Manag 10 (2014), 383–393.
41. Chen, Y., Geis, C., Sommer, C., Activation of TRPV1 contributes to morphine tolerance: involvement of the mitogen-activated protein kinase signaling pathway. J Neurosci 28 (2008), 5836–5845.
42. Chu, L.F., Angst, M.S., Clark, D., Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations. Clin J Pain 24 (2008), 479–496.
43. Chu, L.F., Clark, D.J., Angst, M.S., Opioid tolerance and hyperalgesia in chronic pain patients after one month of oral morphine therapy: a preliminary prospective study. J Pain 7 (2006), 43–48.
44. Chu, L.F., D'Arcy, N., Brady, C., Zamora, A.K., Young, C.A., Kim, J.E., Clemenson, A.M., Angst, M.S., Clark, J.D., Analgesic tolerance without demonstrable opioid-induced hyperalgesia: a double-blinded, randomized, placebo-controlled trial of sustained-release morphine for treatment of chronic nonradicular low-back pain. Pain 153 (2012), 1583–1592.
45. Chu, L.F., Dairmont, J., Zamora, A.K., Young, C.A., Angst, M.S., The endogenous opioid system is not involved in modulation of opioid-induced hyperalgesia. J Pain 12 (2011), 108–115.
46. Coller, J.K., Christrup, L.L., Somogyi, A.A., Role of active metabolites in the use of opioids. Eur J Clin Pharmacol 65 (2009), 121–139.
47. Compton, P., Canamar, C.P., Hillhouse, M., Ling, W., Hyperalgesia in heroin dependent patients and the effects of opioid substitution therapy. J Pain 13 (2012), 401–409.
48. Compton, P., Charuvastra, V.C., Ling, W., Pain intolerance in opioid-maintained former opiate addicts: effect of long-acting maintenance agent. Drug Alcohol Depend 63 (2001), 139–146.
49. Convertino, M., Samoshkin, A., Gauthier, J., Gold, M.S., Maixner, W., Dokholyan, N.V., Diatchenko, L., Mu-opioid receptor 6-transmembrane isoform: a potential therapeutic target for new effective opioids. Prog Neuropsychopharmacol Biol Psychiatry 62 (2015), 61–67.
50. Corder, G., Doolen, S., Donahue, R.R., Winter, M.K., Jutras, B.L., He, Y., Hu, X., Wieskopf, J.S., Mogil, J.S., Storm, D.R., Wang, Z.J., McCarson, K.E., Taylor, B.K., Constitutive mu-opioid receptor activity leads to long-term endogenous analgesia and dependence. Science (New York, NY) 341 (2013), 1394–1399.
51. Coull, J.A., Beggs, S., Boudreau, D., Boivin, D., Tsuda, M., Inoue, K., Gravel, C., Salter, M.W., De Koninck, Y., BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain. Nature 438 (2005), 1017–1021.
52. Coull, J.A., Boudreau, D., Bachand, K., Prescott, S.A., Nault, F., Sik, A., De Koninck, P., De Koninck, Y., Trans-synaptic shift in anion gradient in spinal lamina I neurons as a mechanism of neuropathic pain. Nature 424 (2003), 938–942.
53. Crain, S.M., Shen, K.F., Neuraminidase inhibitor, oseltamivir blocks GM1 ganglioside-regulated excitatory opioid receptor-mediated hyperalgesia, enhances opioid analgesia and attenuates tolerance in mice. Brain Res 995 (2004), 260–266.
54. Crofford, L.J., Adverse effects of chronic opioid therapy for chronic musculoskeletal pain. Nat Rev Rheumatol 6 (2010), 191–197.
55. Cvrcek, P., Side effects of ketamine in the long-term treatment of neuropathic pain. Pain Med 9 (2008), 253–257.
56. Dalva, M.B., Takasu, M.A., Lin, M.Z., Shamah, S.M., Hu, L., Gale, N.W., Greenberg, M.E., EphB receptors interact with NMDA receptors and regulate excitatory synapse formation. Cell 103 (2000), 945–956.
57. Dang, V.C., Christie, M.J., Mechanisms of rapid opioid receptor desensitization, resensitization and tolerance in brain neurons. Br J Pharmacol 165 (2012), 1704–1716.
58. de Araujo, Lucas G., Alster, P., Brodin, E., Wiesenfeld-Hallin, Z., Differential release of cholecystokinin by morphine in rat spinal cord. Neurosci Lett 245 (1998), 13–16.
59. De Gregori, S., De Gregori, M., Ranzani, G.N., Allegri, M., Minella, C., Regazzi, M., Morphine metabolism, transport and brain disposition. Metab Brain Dis 27 (2012), 1–5.
60. De Leo, J.A., Tawfik, V.L., LaCroix-Fralish, M.L., The tetrapartite synapse: path to CNS sensitization and chronic pain. Pain 122 (2006), 17–21.
61. Denk, F., McMahon, S.B., Tracey, I., Pain vulnerability: a neurobiological perspective. Nat Neurosci 17 (2014), 192–200.
62. Depner, U.B., Reinscheid, R.K., Takeshima, H., Brune, K., Zeilhofer, H.U., Normal sensitivity to acute pain, but increased inflammatory hyperalgesia in mice lacking the nociceptin precursor polypeptide or the nociceptin receptor. Eur J Neurosci 17 (2003), 2381–2387.
63. Descalzi, G., Ikegami, D., Ushijima, T., Nestler, E.J., Zachariou, V., Narita, M., Epigenetic mechanisms of chronic pain. Trends Neurosci 38 (2015), 237–246.
64. Doehring, A., Geisslinger, G., Lotsch, J., Epigenetics in pain and analgesia: an imminent research field. Eur J Pain 15 (2011), 11–16.
65. Doehring, A., Oertel, B.G., Sittl, R., Lotsch, J., Chronic opioid use is associated with increased DNA methylation correlating with increased clinical pain. Pain 154 (2013), 15–23.
66. Dogrul, A., Ossipov, M.H., Porreca, F., Differential mediation of descending pain facilitation and inhibition by spinal 5HT-3 and 5HT-7 receptors. Brain Res 1280 (2009), 52–59.
67. Donaldson, R., Sun, Y., Liang, D.Y., Zheng, M., Sahbaie, P., Dill, D.L., Peltz, G., Buck, K.J., Clark, J.D., The multiple PDZ domain protein Mpdz/MUPP1 regulates opioid tolerance and opioid-induced hyperalgesia. BMC Genomics, 17, 2016, 313.
68. Donovan-Rodriguez, T., Urch, C.E., Dickenson, A.H., Evidence of a role for descending serotonergic facilitation in a rat model of cancer-induced bone pain. Neurosci Lett 393 (2006), 237–242.
69. Dourish, C.T., O'Neill, M.F., Schaffer, L.W., Siegl, P.K., Iversen, S.D., The cholecystokinin receptor antagonist devazepide enhances morphine-induced analgesia but not morphine-induced respiratory depression in the squirrel monkey. J Pharmacol Exp Ther 255 (1990), 1158–1165.
70. Drdla, R., Gassner, M., Gingl, E., Sandkuhler, J., Induction of synaptic long-term potentiation after opioid withdrawal. Science (New York, NY) 325 (2009), 207–210.
71. Drdla-Schutting, R., Benrath, J., Wunderbaldinger, G., Sandkuhler, J., Erasure of a spinal memory trace of pain by a brief, high-dose opioid administration. Science (New York, NY) 335 (2012), 235–238.
72. Due, M.R., Piekarz, A.D., Wilson, N., Feldman, P., Ripsch, M.S., Chavez, S., Yin, H., Khanna, R., White, F.A., Neuroexcitatory effects of morphine-3-glucuronide are dependent on Toll-like receptor 4 signaling. J Neuroinflammation, 9, 2012, 200.
73. Duttaroy, A., Yoburn, B.C., The effect of intrinsic efficacy on opioid tolerance. Anesthesiology 82 (1995), 1226–1236.
74. Eidson, L.N., Murphy, A.Z., Blockade of Toll-like receptor 4 attenuates morphine tolerance and facilitates the pain relieving properties of morphine. J Neurosci 33 (2013), 15952–15963.
75. Eidson, L.N., Murphy, A.Z., Persistent peripheral inflammation attenuates morphine-induced periaqueductal gray glial cell activation and analgesic tolerance in the male rat. J Pain 14 (2013), 393–404.
76. Elhabazi, K., Ayachi, S., Ilien, B., Simonin, F., Assessment of morphine-induced hyperalgesia and analgesic tolerance in mice using thermal and mechanical nociceptive modalities. J Vis Exp: JoVE, 2014, e51264.
77. Elhabazi, K., Trigo, J.M., Mollereau, C., Mouledous, L., Zajac, J.M., Bihel, F., Schmitt, M., Bourguignon, J.J., Meziane, H., Petit-demouliere, B., Bockel, F., Maldonado, R., Simonin, F., Involvement of neuropeptide FF receptors in neuroadaptive responses to acute and chronic opiate treatments. Br J Pharmacol 165 (2012), 424–435.
78. Erbs, E., Faget, L., Ceredig, R.A., Matifas, A., Vonesch, J.L., Kieffer, B.L., Massotte, D., Impact of chronic morphine on delta opioid receptor-expressing neurons in the mouse hippocampus. Neuroscience 313 (2016), 46–56.
79. Faris, P.L., Komisaruk, B.R., Watkins, L.R., Mayer, D.J., Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. Science (New York, NY) 219 (1983), 310–312.
80. Ferrini, F., Trang, T., Mattioli, T.A., Laffray, S., Del'Guidice, T., Lorenzo, L.E., Castonguay, A., Doyon, N., Zhang, W., Godin, A.G., Mohr, D., Beggs, S., Vandal, K., Beaulieu, J.M., Cahill, C.M., Salter, M.W., De Koninck, Y., Morphine hyperalgesia gated through microglia-mediated disruption of neuronal Cl(−) homeostasis. Nat Neurosci 16 (2013), 183–192.
81. Fishbain, D.A., Cole, B., Lewis, J.E., Gao, J., Rosomoff, R.S., Do opioids induce hyperalgesia in humans? An evidence-based structured review. Pain Med 10 (2009), 829–839.
82. Fletcher, D., Martinez, V., Opioid-induced hyperalgesia in patients after surgery: a systematic review and a meta-analysis. Br J Anaesth 112 (2014), 991–1004.
83. Frankiewicz, T., Potier, B., Bashir, Z.I., Collingridge, G.L., Parsons, C.G., Effects of memantine and MK-801 on NMDA-induced currents in cultured neurones and on synaptic transmission and LTP in area CA1 of rat hippocampal slices. Br J Pharmacol 117 (1996), 689–697.
84. Frolich, N., Dees, C., Paetz, C., Ren, X., Lohse, M.J., Nikolaev, V.O., Zenk, M.H., Distinct pharmacological properties of morphine metabolites at G(i)-protein and beta-arrestin signaling pathways activated by the human mu-opioid receptor. Biochem Pharmacol 81 (2011), 1248–1254.
85. Fujita, W., Gomes, I., Devi, L.A., Heteromers of mu-delta opioid receptors: new pharmacology and novel therapeutic possibilities. Br J Pharmacol 172 (2015), 375–387.
86. Fukagawa, H., Koyama, T., Kakuyama, M., Fukuda, K., Microglial activation involved in morphine tolerance is not mediated by toll-like receptor 4. J Anesth 27 (2013), 93–97.
87. Galeotti, N., Stefano, G.B., Guarna, M., Bianchi, E., Ghelardini, C., Signaling pathway of morphine induced acute thermal hyperalgesia in mice. Pain 123 (2006), 294–305.
88. Gaveriaux-Ruff, C., Opiate-induced analgesia: contributions from mu, delta and kappa opioid receptors mouse mutants. Curr Pharm Des 19 (2013), 7373–7381.
89. Gerhold, K.J., Drdla-Schutting, R., Honsek, S.D., Forsthuber, L., Sandkuhler, J., Pronociceptive and antinociceptive effects of buprenorphine in the spinal cord dorsal horn cover a dose range of four orders of magnitude. J Neurosci 35 (2015), 9580–9594.
90. Gomes, I., Fujita, W., Gupta, A., Saldanha, S.A., Negri, A., Pinello, C.E., Eberhart, C., Roberts, E., Filizola, M., Hodder, P., Devi, L.A., Identification of a mu-delta opioid receptor heteromer-biased agonist with antinociceptive activity. Proc Natl Acad Sci U S A 110 (2013), 12072–12077.
91. Gong, K., Bhargava, A., Jasmin, L., GluN2B N-methyl-D-aspartate receptor and excitatory amino acid transporter 3 are upregulated in primary sensory neurons after 7 days of morphine administration in rats: implication for opiate-induced hyperalgesia. Pain 157 (2016), 147–158.
92. Grace, P.M., Hutchinson, M.R., Maier, S.F., Watkins, L.R., Pathological pain and the neuroimmune interface. Nat Rev Immunol 14 (2014), 217–231.
93. Grace, P.M., Maier, S.F., Watkins, L.R., Opioid-induced central immune signaling: implications for opioid analgesia. Headache 55 (2015), 475–489.
94. Gris, P., Gauthier, J., Cheng, P., Gibson, D.G., Gris, D., Laur, O., Pierson, J., Wentworth, S., Nackley, A.G., Maixner, W., Diatchenko, L., A novel alternatively spliced isoform of the mu-opioid receptor: functional antagonism. Mol Pain, 6, 2010, 33.
95. Gruber-Schoffnegger, D., Drdla-Schutting, R., Honigsperger, C., Wunderbaldinger, G., Gassner, M., Sandkuhler, J., Induction of thermal hyperalgesia and synaptic long-term potentiation in the spinal cord lamina I by TNF-alpha and IL-1beta is mediated by glial cells. J Neurosci 33 (2013), 6540–6551.
96. Guo, W., Miyoshi, K., Dubner, R., Gu, M., Li, M., Liu, J., Yang, J., Zou, S., Ren, K., Noguchi, K., Wei, F., Spinal 5-HT3 receptors mediate descending facilitation and contribute to behavioral hypersensitivity via a reciprocal neuron-glial signaling cascade. Mol Pain, 10, 2014, 35.
97. Gustafsson, H., Afrah, A.W., Stiller, C.O., Morphine-induced in vivo release of spinal cholecystokinin is mediated by delta-opioid receptors–effect of peripheral axotomy. J Neurochem 78 (2001), 55–63.
98. Hampton, S.B., Cavalier, J., Langford, R., The influence of race and gender on pain management: a systematic literature review. Pain Manag Nurs 16 (2015), 968–977.
99. Harland, A.A., Yeomans, L., Griggs, N.W., Anand, J.P., Pogozheva, I.D., Jutkiewicz, E.M., Traynor, J.R., Mosberg, H.I., Further optimization and evaluation of bioavailable, mixed-efficacy mu-opioid receptor (MOR) agonists/delta-opioid receptor (DOR) antagonists: balancing MOR and DOR affinities. J Med Chem 58 (2015), 8952–8969.
100. Haugan, F., Rygh, L.J., Tjolsen, A., Ketamine blocks enhancement of spinal long-term potentiation in chronic opioid treated rats. Acta Anaesthesiol Scand 52 (2008), 681–687.
101. Hay, N., Sonenberg, N., Upstream and downstream of mTOR. Genes Dev 18 (2004), 1926–1945.
102. Hayhurst, C.J., Durieux, M.E., Differential opioid tolerance and opioid-induced hyperalgesia: a clinical reality. Anesthesiology 124 (2016), 483–488.
103. He, L., Li, H., Chen, L., Miao, J., Jiang, Y., Zhang, Y., Xiao, Z., Hanley, G., Li, Y., Zhang, X., LeSage, G., Peng, Y., Yin, D., Toll-like receptor 9 is required for opioid-induced microglia apoptosis. PLoS ONE, 6, 2011, e18190.
104. Heinisch, S., Palma, J., Kirby, L.G., Interactions between chemokine and mu-opioid receptors: anatomical findings and electrophysiological studies in the rat periaqueductal grey. Brain Behav Immun 25 (2011), 360–372.
105. Henderson, J.T., Georgiou, J., Jia, Z., Robertson, J., Elowe, S., Roder, J.C., Pawson, T., The receptor tyrosine kinase EphB2 regulates NMDA-dependent synaptic function. Neuron 32 (2001), 1041–1056.
106. Hina, N., Fletcher, D., Poindessous-Jazat, F., Martinez, V., Hyperalgesia induced by low-dose opioid treatment before orthopaedic surgery: an observational case-control study. Eur J Anaesthesiol 32 (2015), 255–261.
107. Hoffmann, O., Wiesenfeld-Hallin, Z., The CCK-B receptor antagonist Cl 988 reverses tolerance to morphine in rats. NeuroReport 5 (1994), 2565–2568.
108. Holtman, J.R. Jr., Wala, E.P., Characterization of morphine-induced hyperalgesia in male and female rats. Pain 114 (2005), 62–70.
109. Holtman, J.R. Jr., Wala, E.P., Characterization of the antinociceptive and pronociceptive effects of methadone in rats. Anesthesiology 106 (2007), 563–571.
110. Hopkins, E., Rossi, G., Kest, B., Sex differences in systemic morphine analgesic tolerance following intrathecal morphine injections. Brain Res 1014 (2004), 244–246.
111. Horvath, R.J., DeLeo, J.A., Morphine enhances microglial migration through modulation of P2X4 receptor signaling. J Neurosci 29 (2009), 998–1005.
112. Horvath, R.J., Romero-Sandoval, E.A., De Leo, J.A., Inhibition of microglial P2X4 receptors attenuates morphine tolerance, Iba1, GFAP and mu opioid receptor protein expression while enhancing perivascular microglial ED2. Pain 150 (2010), 401–413.
113. Hurle, M.A., Changes in the expression of G protein-coupled receptor kinases and beta-arrestin 2 in rat brain during opioid tolerance and supersensitivity. J Neurochem 77 (2001), 486–492.
114. Hutchinson, M.R., Shavit, Y., Grace, P.M., Rice, K.C., Maier, S.F., Watkins, L.R., Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia. Pharmacol Rev 63 (2011), 772–810.
115. Hutchinson, M.R., Zhang, Y., Shridhar, M., Evans, J.H., Buchanan, M.M., Zhao, T.X., Slivka, P.F., Coats, B.D., Rezvani, N., Wieseler, J., Hughes, T.S., Landgraf, K.E., Chan, S., Fong, S., Phipps, S., Falke, J.J., Leinwand, L.A., Maier, S.F., Yin, H., Rice, K.C., Watkins, L.R., Evidence that opioids may have toll-like receptor 4 and MD-2 effects. Brain Behav Immun 24 (2010), 83–95.
116. Ji, R.R., Berta, T., Nedergaard, M., Glia and pain: is chronic pain a gliopathy?. Pain 154:Suppl 1 (2013), S10–S28.
117. Ji, R.R., Xu, Z.Z., Gao, Y.J., Emerging targets in neuroinflammation-driven chronic pain. Nat Rev Drug Discovery 13 (2014), 533–548.
118. Jiang, B., Shi, Y., Li, H., Kang, L., Ma, L., Decreased morphine analgesia in rat overexpressing beta-arrestin 2 at periaqueductal gray. Neurosci Lett 400 (2006), 150–153.
119. Jin, J.F., Zhu, L.L., Chen, M., Xu, H.M., Wang, H.F., Feng, X.Q., Zhu, X.P., Zhou, Q., The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection. Patient Prefer Adherence 9 (2015), 923–942.
120. Johannes, C.B., Le, T.K., Zhou, X., Johnston, J.A., Dworkin, R.H., The prevalence of chronic pain in United States adults: results of an Internet-based survey. J Pain 11 (2010), 1230–1239.
121. Johnson, J.L., Rolan, P.E., Johnson, M.E., Bobrovskaya, L., Williams, D.B., Johnson, K., Tuke, J., Hutchinson, M.R., Codeine-induced hyperalgesia and allodynia: investigating the role of glial activation. Transl Psychiatry, 4, 2014, e482.
122. Johnston, I.N., Milligan, E.D., Wieseler-Frank, J., Frank, M.G., Zapata, V., Campisi, J., Langer, S., Martin, D., Green, P., Fleshner, M., Leinwand, L., Maier, S.F., Watkins, L.R., A role for proinflammatory cytokines and fractalkine in analgesia, tolerance, and subsequent pain facilitation induced by chronic intrathecal morphine. J Neurosci 24 (2004), 7353–7365.
123. Julius, D., TRP channels and pain. Annu Rev Cell Dev Biol 29 (2013), 355–384.
124. Juni, A., Cai, M., Stankova, M., Waxman, A.R., Arout, C., Klein, G., Dahan, A., Hruby, V.J., Mogil, J.S., Kest, B., Sex-specific mediation of opioid-induced hyperalgesia by the melanocortin-1 receptor. Anesthesiology 112 (2010), 181–188.
125. Juni, A., Klein, G., Kest, B., Morphine hyperalgesia in mice is unrelated to opioid activity, analgesia, or tolerance: evidence for multiple diverse hyperalgesic systems. Brain Res 1070 (2006), 35–44.
126. Juni, A., Klein, G., Kowalczyk, B., Ragnauth, A., Kest, B., Sex differences in hyperalgesia during morphine infusion: effect of gonadectomy and estrogen treatment. Neuropharmacology 54 (2008), 1264–1270.
127. Kalange, A.S., Kokare, D.M., Singru, P.S., Upadhya, M.A., Chopde, C.T., Subhedar, N.K., Central administration of selective melanocortin 4 receptor antagonist HS014 prevents morphine tolerance and withdrawal hyperalgesia. Brain Res 1181 (2007), 10–20.
128. Klein, T., Magerl, W., Nickel, U., Hopf, H.C., Sandkuhler, J., Treede, R.D., Effects of the NMDA-receptor antagonist ketamine on perceptual correlates of long-term potentiation within the nociceptive system. Neuropharmacology 52 (2007), 655–661.
129. Komatsu, T., Sakurada, S., Katsuyama, S., Sanai, K., Sakurada, T., Mechanism of allodynia evoked by intrathecal morphine-3-glucuronide in mice. Int Rev Neurobiol 85 (2009), 207–219.
130. Kranke P, Jokinen J, Pace NL, Schnabel A, Hollmann MW, Hahnenkamp K, Eberhart LH, Poepping DM, Weibel S (2015) Continuous intravenous perioperative lidocaine infusion for postoperative pain and recovery. The Cochrane database of systematic reviews CD009642.
131. Laboureyras, E., Aubrun, F., Monsaingeon, M., Corcuff, J.B., Laulin, J.P., Simonnet, G., Exogenous and endogenous opioid-induced pain hypersensitivity in different rat strains. Pain Res Manag 19 (2014), 191–197.
132. Larcher, A., Laulin, J.P., Celerier, E., Le Moal, M., Simonnet, G., Acute tolerance associated with a single opiate administration: involvement of N-methyl-D-aspartate-dependent pain facilitatory systems. Neuroscience 84 (1998), 583–589.
133. Largent-Milnes, T.M., Guo, W., Wang, H.Y., Burns, L.H., Vanderah, T.W., Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor-Gs coupling. J Pain 9 (2008), 700–713.
134. Laux-Biehlmann, A., Mouheiche, J., Veriepe, J., Goumon, Y., Endogenous morphine and its metabolites in mammals: history, synthesis, localization and perspectives. Neuroscience 233 (2013), 95–117.
135. Law, P.Y., Reggio, P.H., Loh, H.H., Opioid receptors: toward separation of analgesic from undesirable effects. Trends Biochem Sci 38 (2013), 275–282.
136. Lee, M., Silverman, S.M., Hansen, H., Patel, V.B., Manchikanti, L., A comprehensive review of opioid-induced hyperalgesia. Pain Physician 14 (2011), 145–161.
137. Lewis, S.S., Hutchinson, M.R., Rezvani, N., Loram, L.C., Zhang, Y., Maier, S.F., Rice, K.C., Watkins, L.R., Evidence that intrathecal morphine-3-glucuronide may cause pain enhancement via toll-like receptor 4/MD-2 and interleukin-1beta. Neuroscience 165 (2010), 569–583.
138. Li, X., Angst, M.S., Clark, J.D., A murine model of opioid-induced hyperalgesia. Brain Res Mol Brain Res 86 (2001), 56–62.
139. Liang, D., Shi, X., Qiao, Y., Angst, M.S., Yeomans, D.C., Clark, J.D., Chronic morphine administration enhances nociceptive sensitivity and local cytokine production after incision. Mol Pain, 4, 2008, 7.
140. Liang, D.Y., Li, X., Clark, J.D., 5-Hydroxytryptamine type 3 receptor modulates opioid-induced hyperalgesia and tolerance in mice. Anesthesiology 114 (2011), 1180–1189.
141. Liang, D.Y., Li, X., Clark, J.D., Epigenetic regulation of opioid-induced hyperalgesia, dependence, and tolerance in mice. J Pain 14 (2013), 36–47.
142. Liang, D.Y., Liao, G., Wang, J., Usuka, J., Guo, Y., Peltz, G., Clark, J.D., A genetic analysis of opioid-induced hyperalgesia in mice. Anesthesiology 104 (2006), 1054–1062.
143. Liang, D.Y., Sun, Y., Shi, X.Y., Sahbaie, P., Clark, J.D., Epigenetic regulation of spinal cord gene expression controls opioid-induced hyperalgesia. Mol Pain, 10, 2014, 59.
144. Liang, D.Y., Zheng, M., Sun, Y., Sahbaie, P., Low, S.A., Peltz, G., Scherrer, G., Flores, C., Clark, J.D., The Netrin-1 receptor DCC is a regulator of maladaptive responses to chronic morphine administration. BMC Genomics, 15, 2014, 345.
145. Lin, C.P., Kang, K.H., Lin, T.H., Wu, M.Y., Liou, H.C., Chuang, W.J., Sun, W.Z., Fu, W.M., Role of spinal CXCL1 (GROalpha) in opioid tolerance: a human-to-rodent translational study. Anesthesiology 122 (2015), 666–676.
146. Lin, S.L., Chang, F.L., Ho, S.Y., Charoenkwan, P., Wang, K.W., Huang, H.L., Predicting neuroinflammation in morphine tolerance for tolerance therapy from immunostaining images of rat spinal cord. PLoS ONE, 10, 2015, e0139806.
147. Little, J.W., Cuzzocrea, S., Bryant, L., Esposito, E., Doyle, T., Rausaria, S., Neumann, W.L., Salvemini, D., Spinal mitochondrial-derived peroxynitrite enhances neuroimmune activation during morphine hyperalgesia and antinociceptive tolerance. Pain 154 (2013), 978–986.
148. Liu, X., Sandkuhler, J., Characterization of long-term potentiation of C-fiber-evoked potentials in spinal dorsal horn of adult rat: essential role of NK1 and NK2 receptors. J Neurophysiol 78 (1997), 1973–1982.
149. Lopez-Garcia, J.A., Serotonergic modulation of spinal sensory circuits. Curr Top Med Chem 6 (2006), 1987–1996.
150. Lotsch, J., Pleiotropic effects of morphine-6beta-glucuronide. Anesthesiology 110 (2009), 1209–1210.
151. Lotsch, J., Geisslinger, G., A critical appraisal of human genotyping for pain therapy. Trends Pharmacol Sci 31 (2010), 312–317.
152. Lu, C., Shi, L., Zhang, J., Kong, M., Liu, Y., Zhou, Y., Xu, L., He, J., Ma, Z., Gu, X., Neuron-restrictive silencer factor in periaqueductal gray contributes to remifentanil-induced postoperative hyperalgesia via repression of the mu-opioid receptor. J Neurol Sci 352 (2015), 48–52.
153. Luo, X., Wang, X., Xia, Z., Chung, S.K., Cheung, C.W., CXCL12/CXCR4 axis: an emerging neuromodulator in pathological pain. Rev Neurosci 27 (2016), 83–92.
154. Lutz, B.M., Nia, S., Xiong, M., Tao, Y.X., Bekker, A., MTOR, a new potential target for chronic pain and opioid-induced tolerance and hyperalgesia. Mol Pain, 11, 2015, 32.
155. Machelska, H., Control of neuropathic pain by immune cells and opioids. CNS Neurol Disord: Drug Targets 10 (2011), 559–570.
156. Mann, A., Illing, S., Miess, E., Schulz, S., Different mechanisms of homologous and heterologous mu-opioid receptor phosphorylation. Br J Pharmacol 172 (2015), 311–316.
157. Mao, J., Price, D.D., Mayer, D.J., Thermal hyperalgesia in association with the development of morphine tolerance in rats: roles of excitatory amino acid receptors and protein kinase C. J Neurosci 14 (1994), 2301–2312.
158. Mao, J., Sung, B., Ji, R.R., Lim, G., Chronic morphine induces downregulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensitivity. J Neurosci 22 (2002), 8312–8323.
159. Mapplebeck, J.C., Beggs, S., Salter, M.W., Sex differences in pain: a tale of two immune cells. Pain 157:Suppl 1 (2016), S2–S6.
160. Massotte, D., In vivo opioid receptor heteromerization: where do we stand?. Br J Pharmacol 172 (2015), 420–434.
161. Matthes, H.W.D., Maldonado, R., Simonin, F., Valverde, O., Slowe, S., Kitchen, I., Befort, K., Dierich, A., LeMeur, M., Dollé, P., Tzavara, E., Hanoune, J., Roques, B.P., Kieffer, B.L., Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the μ-opioid receptor gene. Nature 383 (1996), 819–823.
162. Mattioli, T.A., Leduc-Pessah, H., Skelhorne-Gross, G., Nicol, C.J., Milne, B., Trang, T., Cahill, C.M., Toll-like receptor 4 mutant and null mice retain morphine-induced tolerance, hyperalgesia, and physical dependence. PLoS ONE, 9, 2014, e97361.
163. Mauermann, E., Filitz, J., Dolder, P., Rentsch, K.M., Bandschapp, O., Ruppen, W., Does fentanyl lead to opioid-induced hyperalgesia in healthy volunteers?: A double-blind, randomized, crossover trial. Anesthesiology 124 (2016), 453–463.
164. Mayer, D.J., Mao, J., Holt, J., Price, D.D., Cellular mechanisms of neuropathic pain, morphine tolerance, and their interactions. Proc Natl Acad Sci U S A 96 (1999), 7731–7736.
165. McNally, G.P., Pain facilitatory circuits in the mammalian central nervous system: their behavioral significance and role in morphine analgesic tolerance. Neurosci Biobehav Rev 23 (1999), 1059–1078.
166. Melik Parsadaniantz, S., Rivat, C., Rostene, W., Reaux-Le Goazigo, A., Opioid and chemokine receptor crosstalk: a promising target for pain therapy?. Nat Rev Neurosci 16 (2015), 69–78.
167. Mercadante, S., Arcuri, E., Hyperalgesia and opioid switching. Am J Hosp Palliat Care 22 (2005), 291–294.
168. Mercadante, S., Bruera, E., Opioid switching in cancer pain: from the beginning to nowadays. Crit Rev Oncol/Hematol 99 (2016), 241–248.
169. Mercadante, S., Ferrera, P., Villari, P., Casuccio, A., Intravaia, G., Mangione, S., Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit. J Pain Symptom Manage 37 (2009), 632–641.
170. Merighi, S., Gessi, S., Varani, K., Fazzi, D., Stefanelli, A., Borea, P.A., Morphine mediates a proinflammatory phenotype via mu-opioid receptor-PKCvarepsilon-Akt-ERK1/2 signaling pathway in activated microglial cells. Biochem Pharmacol 86 (2013), 487–496.
171. Mika, J., Zychowska, M., Popiolek-Barczyk, K., Rojewska, E., Przewlocka, B., Importance of glial activation in neuropathic pain. Eur J Pharmacol 716 (2013), 106–119.
172. Milne, B., Jhamandas, K., Sutak, M., Grenier, P., Cahill, C.M., Stereo-selective inhibition of spinal morphine tolerance and hyperalgesia by an ultra-low dose of the alpha-2-adrenoceptor antagonist efaroxan. Eur J Pharmacol 702 (2013), 227–234.
173. Milne, B., Sutak, M., Cahill, C.M., Jhamandas, K., Low doses of alpha 2-adrenoceptor antagonists augment spinal morphine analgesia and inhibit development of acute and chronic tolerance. Br J Pharmacol 155 (2008), 1264–1278.
174. Mogil, J.S., Sex differences in pain and pain inhibition: multiple explanations of a controversial phenomenon. Nat Rev Neurosci 13 (2012), 859–866.
175. Mosberg, H.I., Yeomans, L., Anand, J.P., Porter, V., Sobczyk-Kojiro, K., Traynor, J.R., Jutkiewicz, E.M., Development of a bioavailable mu opioid receptor (MOPr) agonist, delta opioid receptor (DOPr) antagonist peptide that evokes antinociception without development of acute tolerance. J Med Chem 57 (2014), 3148–3153.
176. Mouledous, L., Mollereau, C., Zajac, J.M., Opioid-modulating properties of the neuropeptide FF system. BioFactors 36 (2010), 423–429.
177. Muscoli, C., Doyle, T., Dagostino, C., Bryant, L., Chen, Z., Watkins, L.R., Ryerse, J., Bieberich, E., Neumman, W., Salvemini, D., Counter-regulation of opioid analgesia by glial-derived bioactive sphingolipids. J Neurosci 30 (2010), 15400–15408.
178. Ninkovic, J., Roy, S., Role of the mu-opioid receptor in opioid modulation of immune function. Amino Acids 45 (2013), 9–24.
179. Niu, Z., Ma, J., Chu, H., Zhao, Y., Feng, W., Cheng, Y., Melanocortin 4 receptor antagonists attenuates morphine antinociceptive tolerance, astroglial activation and cytokines expression in the spinal cord of rat. Neurosci Lett 529 (2012), 112–117.
180. Ohnesorge, H., Feng, Z., Zitta, K., Steinfath, M., Albrecht, M., Bein, B., Influence of clonidine and ketamine on m-RNA expression in a model of opioid-induced hyperalgesia in mice. PLoS ONE, 8, 2013, e79567.
181. Oladosu, F.A., Conrad, M.S., O'Buckley, S.C., Rashid, N.U., Slade, G.D., Nackley, A.G., Mu opioid splice variant MOR-1K contributes to the development of opioid-induced hyperalgesia. PLoS ONE, 10, 2015, e0135711.
182. Old, E.A., Clark, A.K., Malcangio, M., The role of glia in the spinal cord in neuropathic and inflammatory pain. Handb Exp Pharmacol 227 (2015), 145–170.
183. Ong, E.W., Cahill, C.M., Molecular perspectives for mu/delta opioid receptor heteromers as distinct, functional receptors. Cells 3 (2014), 152–179.
184. Ossipov, M.H., Lai, J., Vanderah, T.W., Porreca, F., Induction of pain facilitation by sustained opioid exposure: relationship to opioid antinociceptive tolerance. Life Sci 73 (2003), 783–800.
185. Pan, Z.Z., Mu-Opposing actions of the kappa-opioid receptor. Trends Pharmacol Sci 19 (1998), 94–98.
186. Parkhurst, C.N., Yang, G., Ninan, I., Savas, J.N., Yates, J.R. 3rd, Lafaille, J.J., Hempstead, B.L., Littman, D.R., Gan, W.B., Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor. Cell 155 (2013), 1596–1609.
187. Pasternak, G.W., Pan, Y.X., Mu opioids and their receptors: evolution of a concept. Pharmacol Rev 65 (2013), 1257–1317.
188. Por, E.D., Bierbower, S.M., Berg, K.A., Gomez, R., Akopian, A.N., Wetsel, W.C., Jeske, N.A., Beta-Arrestin-2 desensitizes the transient receptor potential vanilloid 1 (TRPV1) channel. J Biol Chem 287 (2012), 37552–37563.
189. Posillico, C.K., Terasaki, L.S., Bilbo, S.D., Schwarz, J.M., Examination of sex and minocycline treatment on acute morphine-induced analgesia and inflammatory gene expression along the pain pathway in Sprague-Dawley rats. Biol Sex Differ, 6, 2015, 33.
190. Qiu, S., Feng, Y., LeSage, G., Zhang, Y., Stuart, C., He, L., Li, Y., Caudle, Y., Peng, Y., Yin, D., Chronic morphine-induced microRNA-124 promotes microglial immunosuppression by modulating P65 and TRAF6. J Immunol 194 (2015), 1021–1030.
191. Raghavendra, V., Rutkowski, M.D., DeLeo, J.A., The role of spinal neuroimmune activation in morphine tolerance/hyperalgesia in neuropathic and sham-operated rats. J Neurosci 22 (2002), 9980–9989.
192. Raghavendra, V., Tanga, F.Y., DeLeo, J.A., Attenuation of morphine tolerance, withdrawal-induced hyperalgesia, and associated spinal inflammatory immune responses by propentofylline in rats. Neuropsychopharmacology 29 (2004), 327–334.
193. Ramasubbu, C., Gupta, A., Pharmacological treatment of opioid-induced hyperalgesia: a review of the evidence. J Pain Palliat Care Pharmacother 25 (2011), 219–230.
194. Ren, K., Dubner, R., Activity-triggered tetrapartite neuron-glial interactions following peripheral injury. Curr Opin Pharmacol 26 (2015), 16–25.
195. Renfrey, S., Downton, C., Featherstone, J., The painful reality. Nat Rev Drug Discovery 2 (2003), 175–176.
196. Richebe, P., Cahana, A., Rivat, C., Tolerance and opioid-induced hyperalgesia. Is a divorce imminent?. Pain 153 (2012), 1547–1548.
197. Richebe, P., Rivat, C., Laulin, J.P., Maurette, P., Simonnet, G., Ketamine improves the management of exaggerated postoperative pain observed in perioperative fentanyl-treated rats. Anesthesiology 102 (2005), 421–428.
198. Rivat, C., Sebaihi, S., Van Steenwinckel, J., Fouquet, S., Kitabgi, P., Pohl, M., Melik Parsadaniantz, S., Reaux-Le Goazigo, A., Src family kinases involved in CXCL12-induced loss of acute morphine analgesia. Brain Behav Immun 38 (2014), 38–52.
199. Rivat, C., Vera-Portocarrero, L.P., Ibrahim, M.M., Mata, H.P., Stagg, N.J., De Felice, M., Porreca, F., Malan, T.P., Spinal NK-1 receptor-expressing neurons and descending pathways support fentanyl-induced pain hypersensitivity in a rat model of postoperative pain. Eur J Neurosci 29 (2009), 727–737.
200. Rizzi, A., Nazzaro, C., Marzola, G.G., Zucchini, S., Trapella, C., Guerrini, R., Zeilhofer, H.U., Regoli, D., Calo, G., Endogenous nociceptin/orphanin FQ signalling produces opposite spinal antinociceptive and supraspinal pronociceptive effects in the mouse formalin test: pharmacological and genetic evidences. Pain 124 (2006), 100–108.
201. Rothman, R.B., A review of the role of anti-opioid peptides in morphine tolerance and dependence. Synapse 12 (1992), 129–138.
202. Rowan, M.P., Bierbower, S.M., Eskander, M.A., Szteyn, K., Por, E.D., Gomez, R., Veldhuis, N., Bunnett, N.W., Jeske, N.A., Activation of mu opioid receptors sensitizes transient receptor potential vanilloid type 1 (TRPV1) via beta-arrestin-2-mediated cross-talk. PLoS ONE, 9, 2014, e93688.
203. Rowan, M.P., Szteyn, K., Doyle, A.P., Gomez, R., Henry, M.A., Jeske, N.A., Beta-arrestin-2-biased agonism of delta opioid receptors sensitizes transient receptor potential vanilloid type 1 (TRPV1) in primary sensory neurons. Mol Pain, 10, 2014, 50.
204. Ruscheweyh, R., Wilder-Smith, O., Drdla, R., Liu, X.G., Sandkuhler, J., Long-term potentiation in spinal nociceptive pathways as a novel target for pain therapy. Mol Pain, 7, 2011, 20.
205. Sacerdote, P., Franchi, S., Panerai, A.E., Non-analgesic effects of opioids: mechanisms and potential clinical relevance of opioid-induced immunodepression. Curr Pharm Des 18 (2012), 6034–6042.
206. Sahbaie, P., Liang, D.Y., Shi, X.Y., Sun, Y., Clark, J.D., Epigenetic regulation of spinal cord gene expression contributes to enhanced postoperative pain and analgesic tolerance subsequent to continuous opioid exposure. Mol Pain, 12, 2016.
207. Salvemini, D., Doyle, T., Kress, M., Nicol, G., Therapeutic targeting of the ceramide-to-sphingosine 1-phosphate pathway in pain. Trends Pharmacol Sci 34 (2013), 110–118.
208. Samoshkin, A., Convertino, M., Viet, C.T., Wieskopf, J.S., Kambur, O., Marcovitz, J., Patel, P., Stone, L.S., Kalso, E., Mogil, J.S., Schmidt, B.L., Maixner, W., Dokholyan, N.V., Diatchenko, L., Structural and functional interactions between six-transmembrane mu-opioid receptors and beta2-adrenoreceptors modulate opioid signaling. Sci Rep, 5, 2015, 18198.
209. Sandkuhler, J., Models and mechanisms of hyperalgesia and allodynia. Physiol Rev 89 (2009), 707–758.
210. Sanna, M.D., Ghelardini, C., Galeotti, N., Regionally selective activation of ERK and JNK in morphine paradoxical hyperalgesia: a step toward improving opioid pain therapy. Neuropharmacology 86 (2014), 67–77.
211. Sanna, M.D., Ghelardini, C., Galeotti, N., Activation of JNK pathway in spinal astrocytes contributes to acute ultra-low-dose morphine thermal hyperalgesia. Pain 156 (2015), 1265–1275.
212. Sanna, M.D., Mello, T., Ghelardini, C., Galeotti, N., Inhibition of spinal ERK1/2-c-JUN signaling pathway counteracts the development of low doses morphine-induced hyperalgesia. Eur J Pharmacol 764 (2015), 271–277.
213. Scanziani, M., Malenka, R.C., Nicoll, R.A., Role of intercellular interactions in heterosynaptic long-term depression. Nature 380 (1996), 446–450.
214. Scherrer, G., Imamachi, N., Cao, Y.Q., Contet, C., Mennicken, F., O'Donnell, D., Kieffer, B.L., Basbaum, A.I., Dissociation of the opioid receptor mechanisms that control mechanical and heat pain. Cell 137 (2009), 1148–1159.
215. Shapovalov, G., Gkika, D., Devilliers, M., Kondratskyi, A., Gordienko, D., Busserolles, J., Bokhobza, A., Eschalier, A., Skryma, R., Prevarskaya, N., Opiates modulate thermosensation by internalizing cold receptor TRPM8. Cell Rep 4 (2013), 504–515.
216. Shurman, J., Koob, G.F., Gutstein, H.B., Opioids, pain, the brain, and hyperkatifeia: a framework for the rational use of opioids for pain. Pain Med 11 (2010), 1092–1098.
217. Silverman, S.M., Opioid induced hyperalgesia: clinical implications for the pain practitioner. Pain Physician 12 (2009), 679–684.
218. Simonin, F., Neuropeptide FF receptors as therapeutic targets. Drugs Future 31 (2006), 603–609.
219. Simonin, F., Schmitt, M., Laulin, J.-P., Laboureyras, E., Jhamandas, J.H., MacTavish, D., Matifas, A., Mollereau, C., Laurent, P., Parmentier, M., Kieffer, B.L., Bourguignon, J.-J., Simonnet, G., RF9, a potent and selective neuropeptide FF receptor antagonist, prevents opioid-induced tolerance associated with hyperalgesia. Proc Natl Acad Sci U S A 103 (2006), 466–471.
220. Simonin, F., Valverde, O., Smadja, S., Slowe, S., Kitchen, I., Dierich, A., Le Meur, M., Roques, B.P., Maldonado, R., Kieffer, B.L., Disruption of the k-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective k-agonist U-50,488H and attenuates morphine withdrawal. EMBO J 17 (1998), 886–897.
221. Skolnick, P., Davis, H., Arnelle, D., Deaver, D., Translational potential of naloxone and naltrexone as TLR4 antagonists. Trends Pharmacol Sci 35 (2014), 431–432.
222. Sorge, R.E., Mapplebeck, J.C., Rosen, S., Beggs, S., Taves, S., Alexander, J.K., Martin, L.J., Austin, J.S., Sotocinal, S.G., Chen, D., Yang, M., Shi, X.Q., Huang, H., Pillon, N.J., Bilan, P.J., Tu, Y., Klip, A., Ji, R.R., Zhang, J., Salter, M.W., Mogil, J.S., Different immune cells mediate mechanical pain hypersensitivity in male and female mice. Nat Neurosci 18 (2015), 1081–1083.
223. Stein, C., Opioid Receptors. Annu Rev Med 67 (2016), 433–451.
224. Stein, C., Machelska, H., Modulation of peripheral sensory neurons by the immune system: implications for pain therapy. Pharmacol Rev 63 (2011), 860–881.
225. Stevens, C.W., Aravind, S., Das, S., Davis, R.L., Pharmacological characterization of LPS and opioid interactions at the toll-like receptor 4. Br J Pharmacol 168 (2013), 1421–1429.
226. Svensson, C.I., Tran, T.K., Fitzsimmons, B., Yaksh, T.L., Hua, X.Y., Descending serotonergic facilitation of spinal ERK activation and pain behavior. FEBS Lett 580 (2006), 6629–6634.
227. Swartjes, M., Mooren, R.A., Waxman, A.R., Arout, C., van de Wetering, K., den Hartigh, J., Beijnen, J.H., Kest, B., Dahan, A., Morphine induces hyperalgesia without involvement of mu-opioid receptor or morphine-3-glucuronide. Mol Med 18 (2012), 1320–1326.
228. Takasu, M.A., Dalva, M.B., Zigmond, R.E., Greenberg, M.E., Modulation of NMDA receptor-dependent calcium influx and gene expression through EphB receptors. Science (New York, NY) 295 (2002), 491–495.
229. Takayama, N., Ueda, H., Morphine-induced chemotaxis and brain-derived neurotrophic factor expression in microglia. J Neurosci 25 (2005), 430–435.
230. Thomas, J., Mustafa, S., Johnson, J., Nicotra, L., Hutchinson, M., The relationship between opioids and immune signalling in the spinal cord. Handb Exp Pharmacol 227 (2015), 207–238.
231. Toll, L., Bruchas, M.R., Calo, G., Cox, B.M., Zaveri, N.T., Nociceptin/orphanin FQ receptor structure, signaling, ligands, functions, and interactions with opioid systems. Pharmacol Rev 68 (2016), 419–457.
232. Trang, T., Al-Hasani, R., Salvemini, D., Salter, M.W., Gutstein, H., Cahill, C.M., Pain and poppies: the good, the bad, and the ugly of opioid analgesics. J Neurosci 35 (2015), 13879–13888.
233. Tsai, R.Y., Tai, Y.H., Tzeng, J.I., Lin, S.L., Shen, C.H., Yang, C.P., Hsin, S.T., Wang, C.B., Wong, C.S., Ultra-low dose naloxone restores the antinociceptive effect of morphine in pertussis toxin-treated rats and prevents glutamate transporter downregulation by suppressing the p38 mitogen-activated protein kinase signaling pathway. Neuroscience 159 (2009), 1244–1256.
234. Tumati, S., Largent-Milnes, T.M., Keresztes, A.I., Yamamoto, T., Vanderah, T.W., Roeske, W.R., Hruby, V.J., Varga, E.V., Tachykinin NK(1) receptor antagonist co-administration attenuates opioid withdrawal-mediated spinal microglia and astrocyte activation. Eur J Pharmacol 684 (2012), 64–70.
235. Uchida, H., Matsushita, Y., Araki, K., Mukae, T., Ueda, H., Histone deacetylase inhibitors relieve morphine resistance in neuropathic pain after peripheral nerve injury. J Pharmacol Sci 128 (2015), 208–211.
236. Vacca, V., Marinelli, S., Luvisetto, S., Pavone, F., Botulinum toxin A increases analgesic effects of morphine, counters development of morphine tolerance and modulates glia activation and mu opioid receptor expression in neuropathic mice. Brain Behav Immun 32 (2013), 40–50.
237. Vanderah, T.W., Suenaga, N.M., Ossipov, M.H., Malan, T.P. Jr., Lai, J., Porreca, F., Tonic descending facilitation from the rostral ventromedial medulla mediates opioid-induced abnormal pain and antinociceptive tolerance. J Neurosci 21 (2001), 279–286.
238. Vardanyan, A., Wang, R., Vanderah, T.W., Ossipov, M.H., Lai, J., Porreca, F., King, T., TRPV1 receptor in expression of opioid-induced hyperalgesia. J Pain 10 (2009), 243–252.
239. Vera-Portocarrero, L.P., Zhang, E.T., King, T., Ossipov, M.H., Vanderah, T.W., Lai, J., Porreca, F., Spinal NK-1 receptor expressing neurons mediate opioid-induced hyperalgesia and antinociceptive tolerance via activation of descending pathways. Pain 129 (2007), 35–45.
240. von Hehn, C.A., Baron, R., Woolf, C.J., Deconstructing the neuropathic pain phenotype to reveal neural mechanisms. Neuron 73 (2012), 638–652.
241. Wala, E.P., Holtman, J.R. Jr., Buprenorphine-induced hyperalgesia in the rat. Eur J Pharmacol 651 (2011), 89–95.
242. Wala, E.P., Sloan, P.A., Holtman, J.R. Jr., Effect of prior treatment with ultra-low-dose morphine on opioid- and nerve injury-induced hyperalgesia in rats. J Opioid Manag 7 (2011), 377–389.
243. Wang, H.B., Zhao, B., Zhong, Y.Q., Li, K.C., Li, Z.Y., Wang, Q., Lu, Y.J., Zhang, Z.N., He, S.Q., Zheng, H.C., Wu, S.X., Hokfelt, T.G., Bao, L., Zhang, X., Coexpression of delta- and mu-opioid receptors in nociceptive sensory neurons. Proc Natl Acad Sci U S A 107 (2010), 13117–13122.
244. Watkins, L.R., Wang, X., Mustafa, S., Hutchinson, M.R., In vivo veritas: (+)-Naltrexone's actions define translational importance: a letter in response to Skolnick et al. ‘Translational potential of naloxone and naltrexone as TLR4 antagonists’. Trends Pharmacol Sci 35 (2014), 432–433.
245. Weibel, R., Reiss, D., Karchewski, L., Gardon, O., Matifas, A., Filliol, D., Becker, J.A., Wood, J.N., Kieffer, B.L., Gaveriaux-Ruff, C., Mu opioid receptors on primary afferent nav1.8 neurons contribute to opiate-induced analgesia: insight from conditional knockout mice. PLoS ONE, 8, 2013, e74706.
246. Williams, J.T., Ingram, S.L., Henderson, G., Chavkin, C., von Zastrow, M., Schulz, S., Koch, T., Evans, C.J., Christie, M.J., Regulation of mu-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. Pharmacol Rev 65 (2013), 223–254.
247. Wilson, N.M., Jung, H., Ripsch, M.S., Miller, R.J., White, F.A., CXCR4 signaling mediates morphine-induced tactile hyperalgesia. Brain Behav Immun 25 (2011), 565–573.
248. Xia, W.S., Peng, Y.N., Tang, L.H., Jiang, L.S., Yu, L.N., Zhou, X.L., Zhang, F.J., Yan, M., Spinal ephrinB/EphB signalling contributed to remifentanil-induced hyperalgesia via NMDA receptor. Eur J Pain 18 (2014), 1231–1239.
249. Xie, J.Y., Herman, D.S., Stiller, C.O., Gardell, L.R., Ossipov, M.H., Lai, J., Porreca, F., Vanderah, T.W., Cholecystokinin in the rostral ventromedial medulla mediates opioid-induced hyperalgesia and antinociceptive tolerance. J Neurosci 25 (2005), 409–416.
250. Xu, J.T., Sun, L., Lutz, B.M., Bekker, A., Tao, Y.X., Intrathecal rapamycin attenuates morphine-induced analgesic tolerance and hyperalgesia in rats with neuropathic pain. Transl Perioper Pain Med 2 (2015), 27–34.
251. Xu, J.T., Zhao, J.Y., Zhao, X., Ligons, D., Tiwari, V., Atianjoh, F.E., Lee, C.Y., Liang, L., Zang, W., Njoku, D., Raja, S.N., Yaster, M., Tao, Y.X., Opioid receptor-triggered spinal mTORC1 activation contributes to morphine tolerance and hyperalgesia. J Clin Investig 124 (2014), 592–603.
252. Xu, J.T., Zhao, X., Yaster, M., Tao, Y.X., Expression and distribution of mTOR, p70S6K, 4E-BP1, and their phosphorylated counterparts in rat dorsal root ganglion and spinal cord dorsal horn. Brain Res 1336 (2010), 46–57.
253. Yaksh, T.L., Woller, S.A., Ramachandran, R., Sorkin, L.S., The search for novel analgesics: targets and mechanisms. F1000Prime Rep, 7, 2015, 56.
254. Yang, H.W., Hu, X.D., Zhang, H.M., Xin, W.J., Li, M.T., Zhang, T., Zhou, L.J., Liu, X.G., Roles of CaMKII, PKA, and PKC in the induction and maintenance of LTP of C-fiber-evoked field potentials in rat spinal dorsal horn. J Neurophysiol 91 (2004), 1122–1133.
255. Zadina, J.E., Nilges, M.R., Morgenweck, J., Zhang, X., Hackler, L., Fasold, M.B., Endomorphin analog analgesics with reduced abuse liability, respiratory depression, motor impairment, tolerance, and glial activation relative to morphine. Neuropharmacology 105 (2015), 215–227.
256. Zeilhofer, H.U., Benke, D., Yevenes, G.E., Chronic pain states: pharmacological strategies to restore diminished inhibitory spinal pain control. Annu Rev Pharmacol Toxicol 52 (2012), 111–133.
257. Zhang, L., Berta, T., Xu, Z.Z., Liu, T., Park, J.Y., Ji, R.R., TNF-alpha contributes to spinal cord synaptic plasticity and inflammatory pain: distinct role of TNF receptor subtypes 1 and 2. Pain 152 (2011), 419–427.
258. Zhang, N., Rogers, T.J., Caterina, M., Oppenheim, J.J., Proinflammatory chemokines, such as C-C chemokine ligand 3, desensitize mu-opioid receptors on dorsal root ganglia neurons. J Immunol 173 (2004), 594–599.
259. Zhao, C.M., Guo, R.X., Hu, F., Meng, J.L., Mo, L.Q., Chen, P.X., Liao, X.X., Cui, Y., Feng, J.Q., Spinal MCP-1 contributes to the development of morphine antinociceptive tolerance in rats. Am J Med Sci 344 (2012), 473–479.
260. Zhao, Y.L., Chen, S.R., Chen, H., Pan, H.L., Chronic opioid potentiates presynaptic but impairs postsynaptic N-methyl-D-aspartic acid receptor activity in spinal cords: implications for opioid hyperalgesia and tolerance. J Biol Chem 287 (2012), 25073–25085.
261. Zhong, Y., Zhou, L.J., Ren, W.J., Xin, W.J., Li, Y.Y., Zhang, T., Liu, X.G., The direction of synaptic plasticity mediated by C-fibers in spinal dorsal horn is decided by Src-family kinases in microglia: the role of tumor necrosis factor-alpha. Brain Behav Immun 24 (2010), 874–880.
262. Zhou, H.Y., Chen, S.R., Chen, H., Pan, H.L., Opioid-induced long-term potentiation in the spinal cord is a presynaptic event. J Neurosci 30 (2010), 4460–4466.
263. Zhu, Y., King, M.A., Schuller, A.G., Nitsche, J.F., Reidl, M., Elde, R.P., Unterwald, E., Pasternak, G.W., Pintar, J.E., Retention of supraspinal delta-like analgesia and loss of morphine tolerance in delta opioid receptor knockout mice. Neuron 24 (1999), 243–252.
264. Zollner, C., Mousa, S.A., Fischer, O., Rittner, H.L., Shaqura, M., Brack, A., Shakibaei, M., Binder, W., Urban, F., Stein, C., Schafer, M., Chronic morphine use does not induce peripheral tolerance in a rat model of inflammatory pain. J Clin Investig 118 (2008), 1065–1073.